Premium
Soft tissue healing around platform‐switching and platform‐matching single implants: A randomized clinical trial
Author(s) -
Cheng GuoLiang,
Leblebicioglu Binnaz,
Li Jianrong,
Chien HuaHong
Publication year - 2020
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1002/jper.20-0030
Subject(s) - medicine , implant , soft tissue , dentistry , osteoprotegerin , wound healing , surgery , receptor , activator (genetics)
Background Implants with platform‐switching (PS) design have been demonstrated to reduce marginal bone loss. However, the influence on peri‐implant soft tissue healing is unclear. This study was designed to investigate its effect on peri‐implant soft tissue healing after implant uncovery. Methods Non‐smokers needing two implants in different quadrants were recruited in this study. For each individual, one PS and one platform‐matching (PM) implants were placed using two‐stage protocol. Following 2 to 8 months of healing, all implants were uncovered and connected to the corresponding healing abutments. Clinical measurements and peri‐implant crevicular fluid (PICF) were taken at 1‐, 2‐, 4‐, and 6‐week after 2nd stage surgery. The cytokine concentrations in PICF were analyzed. Peri‐implant mucosa (1 × 2 × 2 mm) was harvested around the healing abutment for the analysis of gene expression at uncovery and 6‐week post‐uncovery. Results Eighteen participants (nine males; 51.7 ± 14.9 years) were recruited. Compared to PM, PS showed significantly lower probing depth (PD) at 1‐ and 2‐week as well as modified sulcus bleeding index (mSBI) at 1‐, 4‐, and 6‐week ( P < 0.05). Over time, a decrease in osteoprotegerin and interleukin‐1β concentrations in PICF along with an increase in receptor activator of unclear factor kappa‐B ligand, periostin, and peroxidasin gene expressions in peri‐implant mucosa were noted within both groups ( P < 0.05) without significant intergroup differences. Conclusion Within the limits, implants with PS design rendered significant benefits over PM design in PD and mSBI reduction during a 6‐week healing. However, molecular changes within PICF and peri‐implant mucosa as a response to PM and PS appear negligible.